Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS.

Sarah J NagleNirav N ShahAlex GanetskyDaniel J LandsburgSunita D NastaAnthony MatoStephen J SchusterRan ReshefDonald E TsaiJakub Svoboda

Published in: International journal of hematologic oncology (2018)

The rituximab, temozolomide and methotrexate regimen is an effective therapy for patients with PCNSL without the toxicities typically associated with consolidation therapy.

Keyphrases

high dose
diffuse large b cell lymphoma
low dose
stem cell transplantation
newly diagnosed
chronic lymphocytic leukemia
blood brain barrier
stem cells
bone marrow
cell therapy
smoking cessation